Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26
Abstract The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A previously published algorithmic model gave recommendations for which cases to send out for Oncotype DX® (ODX) testing. This study is...
Main Authors: | Bradley M. Turner, Mary Ann Gimenez‐Sanders, Armen Soukiazian, Andrea C. Breaux, Kristin Skinner, Michelle Shayne, Nyrie Soukiazian, Marilyn Ling, David G. Hicks |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2323 |
Similar Items
-
How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01) -
Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01) -
Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01) -
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01) -
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
by: T. M. Aherne, et al.
Published: (2020-04-01)